# Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

> **NCT04574817** · PHASE2 · UNKNOWN · sponsor: **Taizhou Hanzhong biomedical co. LTD** · enrollment: 66 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** HX008

## Key facts

- **NCT ID:** NCT04574817
- **Lead sponsor:** Taizhou Hanzhong biomedical co. LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-28
- **Primary completion:** 2022-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574817, "Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04574817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*